Vanishing corneal epithelial crystals following thalidomide induced resolution of myeloma related paraproteinaemia.
Shuttleworth
G N
GN
Cook
S D
SD
Ropner
J E
JE
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D002330:Carmustine / Q000008:administration & dosage; D003316:Corneal Diseases / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy; D010265:Paraproteinemias / Q000188:drug therapy*; D013792:Thalidomide / Q000627:therapeutic use*; D014792:Visual Acuity
D007166:Immunosuppressive Agents; D013792:Thalidomide; D004317:Doxorubicin; D003520:Cyclophosphamide; D008558:Melphalan; D002330:Carmustine